BR112019008295A2 - composto inibidor de multiquinase, e forma cristalina e utilização do mesmo - Google Patents
composto inibidor de multiquinase, e forma cristalina e utilização do mesmoInfo
- Publication number
- BR112019008295A2 BR112019008295A2 BR112019008295A BR112019008295A BR112019008295A2 BR 112019008295 A2 BR112019008295 A2 BR 112019008295A2 BR 112019008295 A BR112019008295 A BR 112019008295A BR 112019008295 A BR112019008295 A BR 112019008295A BR 112019008295 A2 BR112019008295 A2 BR 112019008295A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline form
- inhibitor compound
- compound
- multikinase inhibitor
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940124303 multikinase inhibitor Drugs 0.000 title 1
- DQFCVOOFMXEPOC-UHFFFAOYSA-N CC1=C2N=C(c3ccccc3Cl)c3cnc(cc3N=C2NN1)N1CCOCC1 Chemical class CC1=C2N=C(c3ccccc3Cl)c3cnc(cc3N=C2NN1)N1CCOCC1 DQFCVOOFMXEPOC-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a um composto conforme representado por fórmula (i) (i) ou um sal farmaceuticamente aceitável e estereoisômero do mesmo, em que r1, r2, x, y, p, w e ar são como definidos na descrição. o composto de fórmula (i) da presente invenção pode ser utilizado na preparação de um fármaco para tratamento de cânceres mediados por anormalidade de multiquinases. também proporcionado é uma forma cristalina i de um composto 4-(5-(2-clorofenil)-3-metil-2,10-diidropirazol [4,3-b]pirido[4,3-e][1,4]diazepin-8-il)morfolina, em que em um padrão de difração de raio x do pó de forma cristalina i, apresenta picos característicos em 7,4 ± 0,2o, 17,9 ± 0,2o, 18,9 ± 0,2o, 19,4 ± 0,2o, 21,5 ± 0,2o e 23,7 ± 0,2o.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611174146.3 | 2016-12-13 | ||
CN201611174146 | 2016-12-13 | ||
CN201710426594.6 | 2017-06-08 | ||
CN201710426594 | 2017-06-08 | ||
CN201710593933 | 2017-07-20 | ||
CN201710593933.X | 2017-07-20 | ||
PCT/CN2017/115698 WO2018108079A1 (zh) | 2016-12-13 | 2017-12-12 | 多激酶抑制剂化合物、其晶型及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112019008295A2 true BR112019008295A2 (pt) | 2019-07-09 |
BR112019008295B1 BR112019008295B1 (pt) | 2024-03-12 |
Family
ID=62557952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019008295-6A BR112019008295B1 (pt) | 2016-12-13 | 2017-12-12 | Composto inibidor de multiquinase, forma cristalina do composto de fórmula iii, formulação/composição farmacêutica, seus usos, métodos para a preparação da forma cristalina e do composto de fórmula iii e intermediário para a preparação do composto de fórmula iii |
Country Status (10)
Country | Link |
---|---|
US (3) | US10208042B1 (pt) |
EP (1) | EP3447056A4 (pt) |
JP (1) | JP6594571B2 (pt) |
KR (1) | KR102373577B1 (pt) |
CN (1) | CN108218868B (pt) |
AU (1) | AU2017376353B2 (pt) |
BR (1) | BR112019008295B1 (pt) |
CA (1) | CA3041155C (pt) |
RU (1) | RU2723985C9 (pt) |
WO (1) | WO2018108079A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108218868B (zh) | 2016-12-13 | 2019-02-19 | 南京药捷安康生物科技有限公司 | 多激酶抑制剂化合物、其晶型及用途 |
JP2023515549A (ja) * | 2020-02-24 | 2023-04-13 | 薬捷安康(南京)科技股▲分▼有限公司 | マルチキナーゼ阻害剤の新規用途 |
US20230212167A1 (en) * | 2020-05-08 | 2023-07-06 | Transthera Sciences (Nanjing), Inc. | Method for synthesizing anti-tumor compound and intermediates thereof |
WO2022197104A1 (ko) * | 2021-03-16 | 2022-09-22 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형 |
KR20230163440A (ko) * | 2021-03-29 | 2023-11-30 | 트랜스테라 사이언시즈 (난징), 인크. | 멀티 키나제 억제제의 병용 응용 |
CN115322196A (zh) * | 2021-05-10 | 2022-11-11 | 药捷安康(南京)科技股份有限公司 | 多激酶抑制剂的药物组合物及其用途 |
TW202320760A (zh) * | 2021-11-27 | 2023-06-01 | 大陸商藥捷安康(南京)科技股份有限公司 | 激酶抑制劑的新用途 |
WO2023104074A1 (zh) * | 2021-12-07 | 2023-06-15 | 药捷安康(南京)科技股份有限公司 | 激酶抑制剂的新用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6440959B1 (en) | 1999-04-21 | 2002-08-27 | Hoffman-La Roche Inc. | Pyrazolobenzodiazepines |
CN101899049A (zh) * | 2004-10-13 | 2010-12-01 | 霍夫曼-拉罗奇有限公司 | 二取代吡唑并苯并二氮杂*类 |
CN102603743B (zh) * | 2012-02-24 | 2014-05-28 | 南京天易生物科技有限公司 | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 |
CN108218868B (zh) | 2016-12-13 | 2019-02-19 | 南京药捷安康生物科技有限公司 | 多激酶抑制剂化合物、其晶型及用途 |
-
2017
- 2017-12-12 CN CN201711317321.4A patent/CN108218868B/zh active Active
- 2017-12-12 EP EP17879808.8A patent/EP3447056A4/en active Pending
- 2017-12-12 JP JP2018567899A patent/JP6594571B2/ja active Active
- 2017-12-12 KR KR1020197015517A patent/KR102373577B1/ko active IP Right Grant
- 2017-12-12 BR BR112019008295-6A patent/BR112019008295B1/pt active IP Right Grant
- 2017-12-12 AU AU2017376353A patent/AU2017376353B2/en active Active
- 2017-12-12 CA CA3041155A patent/CA3041155C/en active Active
- 2017-12-12 WO PCT/CN2017/115698 patent/WO2018108079A1/zh active Application Filing
- 2017-12-12 RU RU2019115518A patent/RU2723985C9/ru active
-
2018
- 2018-10-10 US US16/156,371 patent/US10208042B1/en active Active
-
2019
- 2019-01-25 US US16/257,342 patent/US10889586B2/en active Active
-
2020
- 2020-12-31 US US17/139,452 patent/US11718620B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3041155C (en) | 2021-12-14 |
US10889586B2 (en) | 2021-01-12 |
US20190040064A1 (en) | 2019-02-07 |
EP3447056A4 (en) | 2019-09-18 |
AU2017376353B2 (en) | 2020-02-06 |
WO2018108079A1 (zh) | 2018-06-21 |
AU2017376353A1 (en) | 2019-05-16 |
JP6594571B2 (ja) | 2019-10-23 |
US20190152972A1 (en) | 2019-05-23 |
KR20190068626A (ko) | 2019-06-18 |
EP3447056A1 (en) | 2019-02-27 |
CN108218868A (zh) | 2018-06-29 |
BR112019008295B1 (pt) | 2024-03-12 |
US11718620B2 (en) | 2023-08-08 |
US10208042B1 (en) | 2019-02-19 |
CN108218868B (zh) | 2019-02-19 |
US20210130354A1 (en) | 2021-05-06 |
JP2019518784A (ja) | 2019-07-04 |
RU2723985C9 (ru) | 2020-09-21 |
RU2723985C1 (ru) | 2020-06-18 |
AU2017376353A2 (en) | 2019-06-27 |
KR102373577B1 (ko) | 2022-03-10 |
CA3041155A1 (en) | 2018-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019008295A2 (pt) | composto inibidor de multiquinase, e forma cristalina e utilização do mesmo | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
BR112019008341A2 (pt) | processo para a preparação de pirazolo[1,5-a]pirimidinas e sais dos mesmos | |
PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
NI201400102A (es) | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
MX2014004479A (es) | Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades. | |
BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
MX2021001096A (es) | 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia. | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
MX2018002738A (es) | Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. | |
MX340574B (es) | Imidazo pirazinas. | |
WO2013188268A8 (en) | Topical ophthalmological pharmaceutical composition containing pazopanib | |
CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
UY35359A (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO | |
CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
CU24536B1 (es) | 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7- tetrahidro-3h-pirrolo[2,1-c][1,2,4]triazol-3-onas sustituidas y procedimientos de preparación |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: TRANSTHERA SCIENCES (NANJING), INC. (CN) |
|
B25G | Requested change of headquarter approved |
Owner name: TRANSTHERA SCIENCES (NANJING), INC. (CN) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2017, OBSERVADAS AS CONDICOES LEGAIS |